Banque Cantonale Vaudoise Invests $939,000 in United Therapeutics Corporation $UTHR

Banque Cantonale Vaudoise purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, HoldingsChannel reports. The fund purchased 1,928 shares of the biotechnology company’s stock, valued at approximately $939,000.

Other institutional investors also recently bought and sold shares of the company. Torren Management LLC purchased a new position in United Therapeutics during the fourth quarter worth about $26,000. Activest Wealth Management grew its holdings in United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC acquired a new position in United Therapeutics during the 4th quarter worth approximately $31,000. Wilmington Savings Fund Society FSB grew its holdings in United Therapeutics by 125.6% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 49 shares in the last quarter. Finally, Harbor Capital Advisors Inc. purchased a new stake in shares of United Therapeutics during the 4th quarter worth approximately $48,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $564.11, for a total value of $5,641,100.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,648,140.36. This represents a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nilda Mesa sold 258 shares of the stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $581.93, for a total value of $150,137.94. Following the completion of the sale, the director directly owned 5,028 shares of the company’s stock, valued at $2,925,944.04. This represents a 4.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 569,913 shares of company stock worth $317,603,631 over the last ninety days. Company insiders own 8.60% of the company’s stock.

United Therapeutics Stock Up 0.5%

Shares of NASDAQ:UTHR opened at $568.43 on Friday. The firm has a fifty day moving average of $563.25 and a two-hundred day moving average of $511.57. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The firm has a market capitalization of $24.13 billion, a P/E ratio of 20.98, a price-to-earnings-growth ratio of 1.83 and a beta of 0.60.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the previous year, the company earned $6.63 EPS. Equities research analysts expect that United Therapeutics Corporation will post 27.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on UTHR shares. Morgan Stanley set a $516.00 price objective on shares of United Therapeutics in a research report on Thursday, May 7th. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Raymond James Financial began coverage on shares of United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price target on the stock. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, HC Wainwright lifted their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research note on Tuesday, March 31st. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.